Roche's Alecensa receives EU approval to treat ALK-positive lung cancer

ZURICH (Reuters) - The European Commission has approved Roche's Alecensa as treatment for a form of lung cancer common in patients without a significant smoking history, the Swiss drug maker said on Thursday.